RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
HuaSin Science of Guangzhou obtained exclusive China rights to a test that offers early detection of HPV, a precursor to cervical cancer, from Genomica of Madrid. HuaSin, which will produce the test under its own DiBao label, has started the China registration process and expects a China launch in 2021. HuaSin distributes clinical laboratory instruments, medical devices and reagents, manufactures in vitro diagnostics products and provides thirty-party clinical laboratory services.
Source: China Biotoday
